• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    IKE Tech Welcomes Landmark FDA Recognition of Device-Level Age Verification in Nicotine Regulation

    3/16/26 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ISPR alert in real time by email

    New FDA draft guidance formally acknowledges device-embedded age-gating technology in PMTA review for the first time, signalling the important role that technology and innovation can play in addressing youthusage and access to nicotine products.

    LOS ANGELES, March 16, 2026 /PRNewswire/ -- IKE Tech LLC ("IKE Tech") today welcomed the U.S. Food and Drug Administration's (FDA) draft guidance on Flavored ENDS Premarket Tobacco Product Applications, which formally introduces Device Access Restrictions (DAR) as a consideration in FDA's determination as to whether an ENDS product is Appropriate for the Protection of Public Health (APPH) and continues the Administration's goals of protecting youth health and wellness.

    IKE TECH LLC Logo (PRNewsfoto/IKE Tech LLC/ KCSA)

    The guidance, published in March 2026, represents the first time the FDA has explicitly recognized continuous, device-level, point-of-use age verification as a relevant and valuable factor in determining whether a flavoured nicotine product is APPH and may be lawfully marketed in the United States — a recognition IKE Tech has long called for.

    In April 2025, IKE Tech filed the first-ever component PMTA submission for a standalone, scalable blockchain-based age-gating system, the first of its kind to be accepted for FDA review. The technology provides continuous age verification at the point of use, designed for universal integration across all ENDS devices.

    Commenting on the FDA guidance, Steven Pryzbyla, Board Member, IKE Tech said:

    "This is a long-overdue regulatory acknowledgement of the technology-driven approach we've been advocating for. As CTP has acknowledged, flavors play a recognized role in helping adult smokers transition away from combustible cigarettes.And we agree that a robust compliance infrastructure must exist to ensure that these products remain accessible exclusively for adult use. IKE Tech's PMTA-submitted technology system — the first of its kind — is designed exactly for this purpose, and we welcome FDA's framework as an important step forward."

    IKE Tech's age-gating system — combining Bluetooth Low Energy (BLE) chip technology, advanced biometric verification, and blockchain-secured identity tokenisation via a smartphone-enabled app — was validated in a multi-center Human Factors Study published in April 2025:

    • 100% of users (n=101) successfully completed age verification
    • 0% of underage users were able to activate a device
    • 100% of devices deactivated after inactivity or loss of Bluetooth signal
    • 91% of users rated the app 'Extremely Easy' or 'Very Easy' to use

    The system operates as a continuous lock: only a verified adult user can activate a device, with initial onboarding taking approximately 90 seconds and re-verification just 6 seconds or less.

    Pryzbyla continued: "These results speak directly to the evidentiary standard the FDA's guidance anticipates for DAR technology. With social sourcing and peer sharing cited as the primary routes for minors accessing ENDS products, our innovative technology now successfully moves verification from the point-of-sale to the point-of-use, which is the only intervention point that truly prevents youth access."     

    Beyond youth access, IKE Tech's compliance platform also addresses a second, related challenge: the proliferation of counterfeit and illicit nicotine products that bypass age restrictions, evade tax collection, and expose consumers to unregulated harm. Alongside its age-gating technology, IKE's NFC/RFID smart tag authentication verifies product legitimacy across the supply chain, making counterfeiting detectable, and traceability enforceable.

    IKE Tech sees the FDA's guidance as consistent with the current US administration's MAHA efforts with its focus on attacking the illicit market and preventing youth access to and usage of nicotine products through domestic innovation. The platform was developed and clinically validated in the United States.

    About IKE Tech LLC

    IKE Tech is a SaaS platform providing compliance infrastructure for the nicotine industry globally. Its full-stack technology combines biometric age verification, blockchain-secured product authentication and AI-powered supply chain integrity — enabling manufacturers, retailers and regulators to meet compliance demands at scale. IKE Tech is a joint venture between Ispire Technology (NASDAQ:ISPR), Berify and Chemular.

    IKE Tech filed the first-ever standalone age-gating component PMTA with the FDA in 2025, supported by a published Human Factors Validation Study demonstrating 100% effectiveness at preventing underage device access.

    For general information visit www.iketech.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ike-tech-welcomes-landmark-fda-recognition-of-device-level-age-verification-in-nicotine-regulation-302714278.html

    SOURCE IKE Tech LLC/ KCSA

    Get the next $ISPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPR

    DatePrice TargetRatingAnalyst
    5/20/2024$11.00Buy
    ROTH MKM
    More analyst ratings

    $ISPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    CLO and Secretary Pryzbyla Steven P. sold $29,592 worth of shares (9,000 units at $3.29), decreasing direct ownership by 2% to 390,664 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/17/26 5:53:18 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset Value

    FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirementFDA guidance unlocks an estimated $50 billion total addressable market, allowing companies to lawfully transition the 70% illicit flavored vape market into a compliant ecosystemIspire's 40%-owned IKE Tech joint venture is positioned to generate $5 million to $20 million in annual recurring SaaS revenue per customer in the USBased on conservative SaaS metrics, even a limited number of customers could potentially value the IKE joint venture in the hundreds of millions, dramatically increasing Ispire's book valueIspire-backed IKE Tech was first to file component PMTA for

    3/16/26 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    IKE Tech Welcomes Landmark FDA Recognition of Device-Level Age Verification in Nicotine Regulation

    New FDA draft guidance formally acknowledges device-embedded age-gating technology in PMTA review for the first time, signalling the important role that technology and innovation can play in addressing youthusage and access to nicotine products.LOS ANGELES, March 16, 2026 /PRNewswire/ -- IKE Tech LLC ("IKE Tech") today welcomed the U.S. Food and Drug Administration's (FDA) draft guidance on Flavored ENDS Premarket Tobacco Product Applications, which formally introduces Device Access Restrictions (DAR) as a consideration in FDA's determination as to whether an ENDS product is Appropriate for the Protection of Public Health (APPH) and continues the Administration's goals of protecting youth he

    3/16/26 8:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

    LOS ANGELES, March 11, 2026 /PRNewswire/ -- Ispire Technology Inc. ((ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced that Ispire's management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026. 38th Annual ROTH ConferenceDate: March 22-24, 2026Location: Dana Point, CaliforniaFireside Chat Details: Monday, March 23, 2026, at 8:00 a.m. PT in Blue-Consumer-Salon 2To schedule a one-on-one meeting with the Company's management team, please

    3/11/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Ispire Technology with a new price target

    ROTH MKM initiated coverage of Ispire Technology with a rating of Buy and set a new price target of $11.00

    5/20/24 7:18:59 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    SEC Filings

    View All

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    2/6/26 4:30:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Ispire Technology Inc.

    10-Q - Ispire Technology Inc. (0001948455) (Filer)

    11/6/25 4:31:10 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-K filed by Ispire Technology Inc.

    10-K - Ispire Technology Inc. (0001948455) (Filer)

    9/15/25 4:06:16 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Financials

    Live finance-specific insights

    View All

    Ispire Technology Inc. Reports Financial Results for Fiscal Second Quarter 2026

    Ongoing Focus on Collections Drives 19% Reduction in Net Accounts Receivable since June 30, 2025Cash of $17.6 Million at December 31, 2025  LOS ANGELES, Feb. 6, 2026 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the second quarter of fiscal 2026, for the three months ended December 31, 2025. Fiscal Second Quarter 2026 Financial Results Revenue of $20.3 million versus $41.8 million for the second quarter of fiscal 2025.Gross profit

    2/6/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal Second Quarter 2026 Earnings Conference Call

    LOS ANGELES, Feb. 3, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Friday, February 6, 2026, to discuss the Company's financial results for its fiscal second quarter ended December 31, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Friday, February 6, 2026Time: 8:00 am ETDial-In Number

    2/3/26 7:00:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Schedules Fiscal First Quarter 2026 Earnings Conference Call

    LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, November 6, 2025, to discuss the Company's financial results for its fiscal first quarter ended September 30, 2025. To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call." Date: Thursday, November 6, 2025Time: 8:00 am ETDial-In Nu

    11/4/25 4:05:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ispire-Backed IKE Tech to Spotlight Breakthroughs in Vape Safety and Harm Reduction at World Vape Show Dubai

    President of Ike Tech and SVP of International Nicotine at Ispire, John Patterson, to Join Global Leaders on Industry Innovation Panel LOS ANGELES, June 16, 2025 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ:ISPR), a global leader in vaporization technology and precision dosing, announced its joint venture IKE Tech LLC ("IKE Tech") will spotlight Ike Tech's blockchain based point of use age-gating and Smart-Tag authentication technologies at the World Vape Show Dubai, June 18–20, 2025. John Patterson, president of Ike Tech and senior vice president of International Nicotine at Ispire, will be featured on a high-level panel titled "Innovations in Consumer Safety

    6/16/25 8:30:00 AM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Ispire Technology Inc. Announces Appointment of Jay Yu as Chief Financial Officer

    Jie "Jay" Yu has a strong track record of excellence in public company accounting, and has served in the role of Vice President of Finance for Ispire since June 2023 Ispire also further streamlines operations by cutting an estimated $3.6 million in annual payroll in May 2025 Ispire expects to also cut up to an additional $6.6 million in annual operating expenses over the next three months, for a total estimated annualized expense reduction of $10.2 million LOS ANGELES, May 15, 2025 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today announced the appointment of Jie "Jay" Yu as the

    5/15/25 4:30:00 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $ISPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ispire Technology Inc.

    SC 13G - Ispire Technology Inc. (0001948455) (Subject)

    7/12/24 5:00:02 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care